目的：观察盐酸莫西沙星氯化钠注射液治疗呼吸道中重度感染的疗效及其安全性。方法选取下呼吸道中、重度感染患者150例（男95例，女55例），平均年龄（55.4±9.6）岁，采用序贯给药，即先静脉滴注盐酸莫西沙星注射液0.4 g，1次/d，连用3～5 d后改为口服盐酸莫西沙星片剂，1次/d，0.4g/次，5～14d为1个疗程。结果150例患者中痊愈55例，显效80例，进步10例，总有效率为96.67%（145/150），细菌清除率为88%（80/90），不良反应轻微，未发现明显的肝肾功能损害。结论盐酸莫西沙星对下呼吸道中、重度感染具有良好的疗效，可作为下呼吸道中、重度感染临床的经验性用药。%Objective Observe and evaluate the effect and the safety of moxifloxacin hydrochloride and sodium chloride injection and Moxifloxacin Hydrochloride Tablets in the treatment of respiratory tract infection.Methods Selected 150 patients with moderate to serious lower respiratory tract infection (male 95 cases, female 55 cases, age from 20 years to 89 years, average (55.4±9.6)years. According to the method of sequential dosing, first intravenous drip of moxifloxacin hydrochloride and sodium chloride injection of 0.4 g once a day, continue for 3 - 5 days then change to oral Moxifloxacin Hydrochloride Tablets, once a day, 0.4 g/time. The method considers 5 - 14 days as a period of treatment. Results Among the 150 patients, 55 cases were cured, and 80 cases were treated effectively, and 5 person’s results was progress. The total effective rate was 96.67% (145/150). The bacterial clearance rate was 88% (80/90). There were mild adverse reactions. No damage of liver and kidney function occurred in the course of treatment.Conclusion Moxifloxacin hydrochloride have a good curative effect in the treatment of patients with moderate to serious lower respiratory tract infections. It can be applied as a clinical empirical medication.
展开▼
